Showing Publications By: Erika Lietzan
FDA Resilience after Loper Bright
__ SMU LAW REVIEW __ (forthcoming)
Petition Power
74 AMERICAN UNIVERSITY LAW REVIEW 107 (2024)
User Fee Programs
76 ADMINISTRATIVE LAW REVIEW 375 (Spring 2024)
Solutions Still Searching for a Problem: A Call for Relevant Data to Support “Evergreening” Allegations
33 FORDHAM INTELLECTUAL PROPERTY, MEDIA & ENTERTAINMENT LAW JOURNAL 788 (2023).
The Case of the Missing Device Patents, or: Why Device Patents Matter
33 FORDHAM INTELLECTUAL PROPERTY, MEDIA & ENTERTAINMENT LAW JOURNAL 409 (2022).
Ignoring Drug Trademarks
56 WAKE FOREST LAW REVIEW 945 (2021).
The “Evergreening” Metaphor in Intellectual Property Scholarship
53 AKRON LAW REVIEW 805 (2020).
Early Access to Unapproved Medicines in the United States and France
19 YALE JOURNAL OF HEALTH POLICY, LAW, & ETHICS 1 (2020).
Distorted Drug Patents
95 WASHINGTON LAW REVIEW 1317 (2020).
The Surprising Reach of FDA Regulation of Cannabis, Even after Descheduling
69 AMERICAN UNIVERSITY LAW REVIEW 823 (2019).